Assessment of the use of chloramphenicol at the Neonatal Unit of a Mexican Paediatric Hospital;Evaluación de la utilización del Cloramfenicol en el Servicio de Lactantes de un Hospital Pediátrico Mexicano

Pharmaceutical Care Espana

Volumn 5, Issue 4, 2003, Pages 182-185

  Viso Gurovich, Fela ^a   Gómez Oliván, Leobardo Manuel ^a   González Velasco, Juan Miguel ^a  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE HIDALGO   (Mexico)

Author keywords

Chloramphenicol; Evaluation use the study; Quality of attention; Risk benefit

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; DICLOXACILLIN; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN;

ANAMNESIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; BREAST FEEDING; BRONCHOPNEUMONIA; BRONCHOSPASM; CONFUSION; CONJUNCTIVITIS; CONTACT DERMATITIS; DELIRIUM; DEPRESSION; DIARRHEA; DRUG COST; DRUG POTENTIATION; DRUG UTILIZATION; ENTEROCOLITIS; GASTROINTESTINAL HEMORRHAGE; GLOSSITIS; HEADACHE; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; LARYNGOTRACHEOBRONCHITIS; MALNUTRITION; MEDICAL RECORD; MENINGITIS; MEXICO; NAUSEA; NEWBORN; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; OPHTHALMOPLEGIA; OPTIC NERVE DISEASE; OTITIS MEDIA; PHARYNGITIS; PNEUMONIA; PROSPECTIVE STUDY; RASH; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SHOCK; STOMATITIS; URTICARIA; UTILIZATION REVIEW; VOMITING;

EID: 0041910767     PISSN: 11396202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Secretaría de Salud. Estadísticas Epidemiológicas de morbilidad y mortalidad 1999-2000. SSA (www.ssa.gov).
2. Dukes MNG. Drug utilization studies. Methods and uses. Finland: WHO Regional Publications European Series 1993; 45: 9-21.
3. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy. A Pathophysiologic approach. 4th edition. New York: MC Graw-Hill Medical Publishing Division, 1999: 1978-80, 2043-6.
4. Parfitt K. Martindale. The complete drug reference. 32nd edition, London: Pharmaceutical Press, 1999:182-184.
5. McEvoy GK. AHFS Drug information 2001. Washington: American Society of Health-System Pharmacists, 2001:267-269.
6. Budavari S. The merck index. An encyclopedia of chemicals, drugs and biologicals. 12th edition, New Jersey, 1996: 2116-2117.
7. Kastrup EK. Drug facts and comparisons 1998., St Louis Missouri: Facts and Comparisons, 1998:2283-4.
8. American Medical Association. Drug Evaluations. W.B. Saunders Company, 6th edition, Pennsylvania, 1986: 1419-1423.
9. Dukes MN. Meyler's side effects of drugs. 13th edition, Amsterdam: Elsevier, 1996:730-3.
10. Pelta FR, Vivas RE. Reacciones adversas medicamentosa. Madrid: Díaz de Santos S.A., 1992: 111-3.
11. Davies DM. Textbook of adverse drug reactions. 4th edition, Oxford: Oxford Medical Publications, 1991:36.
12. a edición, Barcelona: Ediciones Científicas y Técnicas S. A., 1993:1-15.
13. Pezzani M, Domecq C, Fresard R, Gonzalez E, Hidalgo J, Papez S. Racionalización del uso de quinolonos y cefalosporinas de tercera generación en un servicio de medicina interna. OFIL 1991; 1:218-222.
14. Dillard K. Appropriate usage of antibiotics improved by surveillance program in the hospitals. JAHA 1997;51:81-85.
15. Abramowitz P. Use of clinical pharmacists to reduce cefamandole, cefoxitin and ticarcillin costs. Am J Hosp Pharm 1982;39:1176-1180.
16. World Organization Health. Case management of acute respiratory infections in children in developing countries. Geneva. WHO Research Development Series No 85.15, 1985.
17. World Organization Health. Guidelines for research on acute respiratory infections. Memorandum from a WHO meeting. Bulletin of the World Health Organization. Geneva 1982; 60(4): 521-533.
18. World Organization Health. Clinical management of acute respiratory infections in children. A WHO Memorandum. Bulletin of the World Health Organization. Geneva 1981; 59(1): 707-716.